NCT00005842 arm group 08a4df479e15ec87e5cf6d58e58b6e85 [clinicaltrials_resource:NCT00005842/arm-group/08a4df479e15ec87e5cf6d58e58b6e85]
NCT00005842 arm group 08a4df479e15ec87e5cf6d58e58b6e85 [clinicaltrials_resource:NCT00005842/arm-group/08a4df479e15ec87e5cf6d58e58b6e85]
Bio2RDF identifier
NCT00005842/arm-group/08a4df479e15ec87e5cf6d58e58b6e85
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltri ...... a4df479e15ec87e5cf6d58e58b6e85
description [clinicaltrials_vocabulary:description]
Patients receive trastuzumab ( ...... nces dose limiting toxicities.
identifier
clinicaltrials_resource:NCT00005842/arm-group/08a4df479e15ec87e5cf6d58e58b6e85
title
NCT00005842 arm group 08a4df479e15ec87e5cf6d58e58b6e85
@en
type
label
NCT00005842 arm group 08a4df47 ...... 4df479e15ec87e5cf6d58e58b6e85]
@en